We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Narrowly Supports Mallinckrodt’s Terlipressin for Liver Disease
Advisory Committee Narrowly Supports Mallinckrodt’s Terlipressin for Liver Disease
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8-7 on Wednesday to support approval of Mallinckrodt’s terlipressin for treatment of hepatorenal syndrome type 1 (HRS-1), a life threatening kidney condition in patients with advanced liver disease.